Search results
Results From The WOW.Com Content Network
Monoamine oxidase inhibitor. Monoamine oxidase inhibitors ( MAOIs) are a class of drugs that inhibit the activity of one or both monoamine oxidase enzymes: monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B). They are best known as effective antidepressants, especially for treatment-resistant depression and atypical depression. [1]
This is a complete list of clinically approved prescription antidepressants throughout the world, as well as clinically approved prescription drugs used to augment antidepressants or mood stabilizers, by pharmacological and/or structural classification.
Aponal, Quitaxon, Sinequan ( doxepin) – a tricyclic antidepressant used to treat nerve pain, insomnia; similar to imipramine. Anquil ( benperidol) – an antipsychotic primarily used to control antisocial hypersexual behaviour. Aricept ( donepezil) – used to slow the progression of Alzheimer's disease. Ativan ( lorazepam) – a ...
Pages in category "Monoamine oxidase inhibitors" The following 101 pages are in this category, out of 101 total. This list may not reflect recent changes. ...
This is a list of investigational antidepressants, or antidepressants that are currently under development for clinical use in the treatment of mood disorders but are not yet approved. All drugs listed are specifically under development for major depressive disorder (MDD) and/or treatment-resistant depression (TRD) unless noted otherwise.
Tyrosine hydroxylase inhibitors. 3-Iodotyrosine • Aquayamycin • Bulbocapnine • Metirosine • Oudenone. Aromatic L-amino acid decarboxylase inhibitors (DOPA decarboxylase inhibitors) Benserazide • Carbidopa • Genistein • Methyldopa. Degradation inhibitors Monoamine oxidase (MAO) inhibitors Selegiline
Tranylcypromine, sold under the brand name Parnate among others, [1] is a monoamine oxidase inhibitor (MAOI). [4] [7] More specifically, tranylcypromine acts as nonselective and irreversible inhibitor of the enzyme monoamine oxidase (MAO). [4] [7] It is used as an antidepressant and anxiolytic agent in the clinical treatment of mood and anxiety ...
Safinamide ( INN; brand name Xadago) is a drug used as an add-on treatment for Parkinson's disease with "off" episodes; it has multiple modes of action, including the inhibition of monoamine oxidase B. [4] [5] [6] It was approved in the European Union in February 2015, [4] in the United States in March 2017, [5] and in Canada in January 2019.